Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. [electronic resource]
Producer: 20160224Description: 325-32 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Anthracyclines -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant -- methods
- Cyclophosphamide -- administration & dosage
- Docetaxel
- Epirubicin -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Humans
- Lapatinib
- Middle Aged
- Neoadjuvant Therapy -- methods
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- biosynthesis
- Taxoids -- administration & dosage
- Trastuzumab -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.